Trillium Therapeutics Inc trades with the ticker TRIL on the TSX and is in the Biotechnology industry.
Overview
As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Cambridge, Massachusetts.
Looking to invest in Trillium Therapeutics Inc? Our analysis brings in the key facts, competitor research and valuation metrics for you to make an informed decision.
Table of Contents
show
TRIL.TO Stock Price and Key Stats
ETF Key Stats
Exchange: TSX
Market Cap : $2426.437MM
PE Ratio:
Price: 50 (Updated: 3/12/2024 0:47:16)
Trillium Therapeutics Inc (TRIL) vs Competitors in Biotechnology
Lets see how TRIL.TO stacks up against others in the Biotechnology asset management industry. We have identified its main peers as:Aeterna Zentaris Inc, Aptose Biosciences Inc, BELLUS Health Inc, Fennec Pharmaceuticals Inc, IMV Inc
.Biotechnology Industry Comparisons
| Company | Market Cap ($MM) | P/E Ratio | EV/EBITDA | Dividend Yield |
|---|---|---|---|---|
| Aeterna Zentaris Inc (AEZS) | $12.674 | N/A | 1.709 | N/A% |
| Aptose Biosciences Inc (APS) | $33.927 | N/A | -0.231 | N/A% |
| BELLUS Health Inc (BLU) | $2,470.298 | N/A | -16.428 | 0.0% |
| Fennec Pharmaceuticals Inc (FRX) | $352.565 | N/A | -21.793 | N/A% |
| IMV Inc (IMV) | $13.117 | N/A | -0.843 | 0.0% |
EV/EBITDA: Enterprise Value to Earnings Before Interest, Taxes, Depreciation, and Amortization – this ratio compares the value of a company, including debt, to the company’s cash earnings less non-cash expenses
Industry: companies that have a lot in common
Market Cap: Market Capitalization – the total value of all a corporation’s stock
N/A: Not Applicable or Not Available
P/E: Price-to-Earnings – this ratio relates a corporation’s share price to its earnings per share
Price: Stock Price – current value to buyers and sellers
Dividend Yield: Dividend or Distribution Yield
Comparisons within Biotechnology
- Trillium Therapeutics Inc (TRIL) vs Aeterna Zentaris Inc (AEZS)
- TRIL has higher EPS (-0.685 vs -6.47). TRIL provides dividends, while AEZS does not. AEZS and TRIL both have P/E’s under 0.
- Trillium Therapeutics Inc (TRIL) vs Aptose Biosciences Inc (APS)
- TRIL has higher EPS (-0.685 vs -10.45). TRIL provides dividends, while APS does not. APS and TRIL both have P/E’s under 0.
- Trillium Therapeutics Inc (TRIL) vs BELLUS Health Inc (BLU)
- TRIL has higher EPS (-0.685 vs -0.96). BLU has higher dividend yield (0.0% vs 0.0%). BLU and TRIL both have P/E’s under 0.
- Trillium Therapeutics Inc (TRIL) vs Fennec Pharmaceuticals Inc (FRX)
- TRIL has higher EPS (-0.685 vs -1.01). TRIL provides dividends, while FRX does not. FRX and TRIL both have P/E’s under 0.
- Trillium Therapeutics Inc (TRIL) vs IMV Inc (IMV)
- TRIL has higher EPS (-0.685 vs -6.11). IMV has higher dividend yield (0.0% vs 0.0%). IMV and TRIL both have P/E’s under 0.
Our Recommendation: Review
May not stand out on key metrics or lacks sufficient data for a strong recommendation.
How to Buy TRIL stock on the TSX
You can buy on pretty much any online brokerage in Canada, since it trades on the TSX. If you are looking for some easy options take a look at these two:| Image | Product Title | Features | Price |
|---|---|---|---|
Editor's Choice  |
| Get $25 Signup Bonus | |
Reliable Pick  |
| Get $50 Free Stock Trades |
